Why undergoing this examination?

Variation in the human genome is one of the factors responsible for modulating individual responses to medications. Pharmacogenetics studies how genetic differences between individuals influence their responses to drugs. The metabolism of a drug consists of various reactions that modify it and generally convert it into a more soluble molecule that can be more easily excreted. Several genes responsible for the expression of enzymes involved in drug metabolism pathways have genetic variants that cause changes in enzyme expression, selectivity, or activity, which result in diverse drug responses. Consequently, assessing the genetic profile based on the analysis of these variants has become essential in aiding the understanding of drug metabolism.

What is the exam?

The MyPharma Basic pharmacogenetic panel evaluates variants in genes responsible for the expression of the main enzymes involved in the metabolism of the medications most commonly used in different therapeutic areas. The analysis provides relevant information on 113 drugs currently most widely used in medicine, based on the recommendations of the main expert consortia: FDA, EMA, Swissmedic, PMDA, and HCSC, through the analysis of genetic variants described in the scientific literature and present in 392 genes.

For whom is it indicated?

• Patients undergoing pharmacological treatment who wish to personalize their medication based on their genetic profile;
• Patients on polypharmacy;
• Patients experiencing side effects from drugs;
• Patients for whom pharmacological treatments have not yielded the expected results.

Technology

SNP array